KMDA - KAMADA LTD
IEX Last Trade
5.98
-0.120 -2.007%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:29:43 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$6.10
-0.12
-1.97%
Fundamental analysis
43%
Profitability
53%
Dept financing
5%
Liquidity
73%
Performance
34%
Performance
5 Days
2.54%
1 Month
4.31%
3 Months
14.15%
6 Months
19.80%
1 Year
-0.58%
2 Year
59.63%
Key data
Stock price
$5.98
DAY RANGE
N/A - N/A
52 WEEK RANGE
$4.86 - $6.53
52 WEEK CHANGE
-$2.73
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/13/2024
Company detail
CEO: Amir London
Region: US
Website: kamada.com
Employees: 360
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kamada.com
Employees: 360
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD. It also provides Bramitob to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity.
Recent news